SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Athena who wrote (297)2/16/1997 1:21:00 AM
From: Brad C. Dunlap   of 6136
 
Hi Athena, IMO book value is of no or little importance when analyzing R&D type companies. Your comments are very well founded and better then I could say. I did find in the horrible bear mkt in biotechs in 1994 there was more analysis on price to book then in the past. All one needs to do is look at the successfull biotechs since then such as AGPH and they certainly didn't perform because of their book value, but rather the performance was due to their respective science.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News